Concurrent Chemoradiation With or Without Durvalumab in Elderly Patients With Unresectable Stage III NSCLC: Safety and EfficacySally C. M. Lau, Adrian G. Sacher, Aline Fusco Fares et al.|JTO Clinical and Research Reports|2021Cited by 11
Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of Anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaC. Shen, Ammar Sukari, William Stokes et al.|International Journal of Radiation Oncology*Biology*Physics|2025Cited by 1